Mouse models of breast cancer in preclinical research

Mi Kyung Park¹, Chang Hoon Lee², Ho Lee¹,3,*

¹Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Gyeonggi, Korea
²College of Pharmacy, Dongguk University, Gyeonggi, Korea
³Carcinogenesis and Metastasis Research Branch, National Cancer Center, Gyeonggi, Korea

Breast cancer remains the second leading cause of cancer death among women, worldwide, despite advances in identifying novel targeted therapies and the development of treating strategies. Classification of clinical subtypes (ER+, PR+, HER2+, and TNBC (Triple-negative)) increases the complexity of breast cancers, which thus necessitates further investigation. Mouse models used in breast cancer research provide an essential approach to examine the mechanisms and genetic pathway in cancer progression and metastasis and to develop and evaluate clinical therapeutics. In this review, we summarize tumor transplantation models and genetically engineered mouse models (GEMMs) of breast cancer and their applications in the field of human breast cancer research and anti-cancer drug development. These models may help to improve the knowledge of underlying mechanisms and genetic pathways, as well as creating approaches for modeling clinical tumor subtypes, and developing innovative cancer therapy.

Keywords: Breast cancer, tumor transplantation model, genetically engineered mouse models

Received 29 November 2018; Accepted 17 December 2018

Breast cancer is the second most common cancer in Korean women [1], with 19,219 cases diagnosed in Korea in 2015 [2]; it is also the second leading cause of cancer-related death among women worldwide [3]. Developing and applying mouse models, using both human tumor xenograft models and genetic modifications, have led to our current understanding of molecular mechanisms that operate during breast cancer progression and metastasis [4]. Breast cancers are classified into five intrinsic subtypes based on hormonal and Human Epidermal growth factor Receptor-2 (HER2) receptor status, namely luminal A (Estrogen Receptor (ER)/Progesterone Receptor (PR)-positive major problem), luminal B (ER/PR-positive, HER-negative, high Ki-67, higher histological grade than luminal A), ER-negative/HER2-positive, HER2-positive, and basal-like triple-negative (ER/PR/HER2-negative) [5]. Treatment of human breast cancer patients is based on the hormone receptor status, specifically ER, PR, and HER2 [6,7], and these hormonal therapies are effective for most patients with hormonal receptor-positive breast cancer; for example, tamoxifen for ER-positive breast cancer and Pertuzumab (Perjeta), Trastuzumab (Herceptin), and Docetaxel (Taxotere) for HER2-positive breast cancer [8-11]. However, primary and acquired resistance to hormonal treatments remains to be resolved [10,12,13]. Xenograft models are used to elucidate the underlying mechanisms of resistance, and genetically engineered mouse models (GEMMs) are also useful to understand the mechanisms involved in the pathogenesis and molecular processes of breast cancer and metastasis. In this review, we summarize several mouse models used in breast cancer research and drug development, and their contribution to understanding the molecular pathways in tumorigenesis and metastasis, providing us invaluable insights into possible developments of innovative cancer...
Mouse models of human breast cancer

Tumor transplantation models

Cell-derived xenografts (CDX), patient-derived xenografts (PDX), and a syngeneic model are well-established tools for evaluating therapeutic efficacy and toxicity and for applying to preclinical assessment (Table 1). CDX transplantation models are useful for investigating breast cancer and metastatic progress [15]. These models are also convenient for investigating genetic alterations that are associated with tumor initiation and growth, but unfortunately show poor clinical predictability.

CDX transplantation models, in which tumor cells are subcutaneously transplanted in nude mice, facilitate straightforward monitoring of tumor growth. Cancer cells in these models show primary tumor growth but do not metastasize [16]. For example, models using BT474 cells (luminal B) [17], as well as MDA-MB-231 [18,19] and MDA-MB-435 cells (triple negative) are well-established [20]. Orthotopic CDX transplantation models in which tumor cells are transplanted to a mammary fat pad of NOD/SCID mice are suitable for studying metastatic functions of genes of interest [21] and to investigate malignant and metastatic phenotypes in mice [4]. Several cancer cell lines, such as MDA-MB-231, MDA-MB-435, and SUM1315 (triple negative), as well as MCF7 and T47D cells (luminal A), are used to generate spontaneous metastasis models of breast cancer through orthotopic injection [22-26]. Metastatic CDX transplantation models in which cancer cells, such as MDA-MB-231 and SUM149 cells, are injected into mouse tail veins are suitable for monitoring experimental metastasis. Taken together, these CDX models allow validation of target genes of interest, and facilitate evaluation of a candidate anti-cancer drug and therapeutics for breast cancer.

In PDX transplantation models, primary human breast carcinomas or tumor fragments are implanted into immune-deficient mice (e.g., nude, NOD/SCID, or NOD/SCID/IL2-receptor null (NSG) mice) subcutaneously or orthotopically [27]. Resulting tumors have characteristics that are similar to those of the original patients’ tumors with respect to histology, genomic signature, and heterogeneity, as well as high predictive drug response [14,28-32]. These models are used to identify biomarkers for personalized drug selection, and to overcome the limitation of CDX transplantation in clinical therapies [33]. While subcutaneous PDX transplantation models have been used in studies to measure primary tumor growth, orthotopic PDX transplantation models are suitable for mechanistic studies of metastasis and therapeutic resistance [34].

Syngeneic mouse models in which murine cancer cells, such as 4T1, are injected into immune-competent mice (e.g. BALB/c) show more effective metastasis, with characteristics similar to those of breast cancer patients. Advantages of these models over CDX transplantation models include the use of immune-competent mice with normal immune cells and immune system, enabling investigation and development of various immune therapies, for example, with anti-PD-1/PD-L1. These models are also useful to investigate the anti-tumor and anti-metastatic effects of multiple drugs due to the high invasiveness of murine cancer cells [35-39]. While CDX transplantation models, in which human cancer cells are injected into immunocompromised mice, are well-established in the study of tumor growth and metastasis and the validation related gene profiles, human cancer cells in these models poorly metastasize and show poorly predictable metastatic characteristics.

Collectively, CDX, PDX, and syngeneic models are well-established for evaluating therapeutic efficacy and toxicity and for applying to preclinical assessment. These models could be critical tools for understanding breast cancer progression, and for evaluating responses to targeted therapeutics, in order to predict therapeutic outcomes for breast cancer patient.

Genetically engineered mouse models

GEMMs of breast cancer have greatly contributed to cancer research, improving understanding and validating human cancer genes, genetic pathways, and therapeutic approaches for cancer, as well as investigating cancer progression and metastasis [40]. They are also essential tools for gene expression profiling in breast cancer progression and metastasis. Histopathological features in over 25 different murine GEMMs of breast cancer have been reported [41]. Promoters frequently used in GEMMs of breast cancer are the mouse mammary tumor virus-long terminal repeat (MMTV-LTR), C3(1), and the whey acidic protein (WAP) promoter, which are used to drive mammary expression of oncogenes, such as neu/ErbB2, cyclin D1, Ras, Myc, and Wnt1 [42]. Promoters, origins, activations, active proteins, incidences, latencies, and pathology subtypes of GEMMs of breast cancer are summarized in Table 2.

ErbB2 (neu/HER2) is the EGFR family of receptor
### Table 1. Brief overview of breast cancer cell line-derived xenograft (CDX), patient-derived xenograft (PDX) and syngeneic mouse models

| Implantation site | Mice strain | Cell line | Subtype | ER | PR | HER2 | References |
|------------------|-------------|-----------|---------|----|----|------|------------|
| **CDX model**    |             |           |         |    |    |      |            |
| subcutaneous     | Subcutaneous| BALB/c, Nude | MDA-MB-231 | Basal | - | - | [18] |
|                  |             |           | MDA-MB-435 | Basal | - | - | [54] |
|                  |             |           | BT-474    | Luminal B | + | + | [55] |
| Orthotopic CDX   | Mammary fat pad | NOD/SCID | MDA-MB-231 | Basal | - | - | [22] |
|                  |             |           | MDA-MB-435 | Basal | - | - | [23] |
|                  |             |           | SUM1315   | Basal | - | - | [24] |
|                  |             |           | MCF7      | Luminal A | + | + | [25] |
|                  |             |           | T47D      | Luminal A | + | + | [26] |
| Metastatic CDX   | Tail vein   | NOD/SCID | MDA-MB-231 | Basal | - | - | [56] |
|                  |             |           | SUM149    | Basal | - | - | [57] |
| **PDX model**    |             |           | Subcutaneous | BALB/c, Nude | [58] |
|                  |             |           | Mammary fat pad | NOD/SCID | [59] |
|                  |             |           | Mammary fat pad | NSG | [60] |
|                  |             |           | Humanized Mammary fat pad | NOD/SCID | [61] |
| **Syngeneic model** | Mammary fat pad | BALB/c | 4T1 | - | - | - | [38] |

### Table 2. Examples of genetically engineered animal tumor models in breast cancer

| Promoter | Origin | Activation | Transgene | Active protein | Primary tumor | Metastasis | Pathology | Subtype |
|----------|--------|------------|-----------|----------------|---------------|------------|-----------|---------|
| MMTV-LTR | Mouse mammary tumor virus | Steroid hormones | *neu/ErbB2* Receptors | 100 30 75 32 | Lung Adenocarcinoma, metastatic luminal | [62] |
| PyMT    | Viral oncogenes | 100 4-8 84-90 14 | Lung, lymph node | Multifocal adenocarcinomas | [63] |
| Cyclin D1 | Cell cycle | 40 88 - - - | Mammary gland adenocarcinomas | [64] |
| Myc     | Cell cycle | 60 - - - | Mammary gland adenocarcinomas | [65] |
| Wnt1    | Differentiation | 60 32 * | Mammary gland adenocarcinomas | [66] |
| C(3)1   | Rat prostate steroid-binding protein (PSBP) | Estrogen | SV40 Tag Viral oncogenes | 90 21 * | Lung, lymph node | Mammary gland adenocarcinomas, Basal | [50] |
| WAP     | Whey acidic protein | Lactogenic hormones | Ras Others | 100 24 14 - | Lung Adenocarcinoma genomic instability | [53] |

*Metastasis/tumor appearance but not incidence was reported.
tyrosine kinases (RTKs) [43], which form homo- and hetero-dimers in response to ligand stimulation, leading to proliferation, differentiation, cell survival, and apoptosis. ErbB2 functions as a prognostic marker, especially in tumors from patients with lymph node metastasis, and predicts poor survival and early relapse in patients [44, 45]. Transgenic mice develop multifocal adenocarcinomas by 30 weeks of age, which metastasize to the lungs [46,47].

Mammary gland-specific expression of the polyoma middle T antigen (PyMT) -under the control of the MMTV promoter- exhibits multifocal adenocarcinomas with a short median latency, high penetrance, and metastasis to the lungs and lymph nodes. These transgenic mice develop palpable tumors at 4-8 weeks of age, and 84-90% of them show pulmonary metastasis by 14 weeks of age [46]. Pathology of these mice is very similar to that of human breast cancer, regarding hyperplasia, adenoma, and early or late carcinoma [46].

Cyclin D1 has been known to play a critical role in the development of normal alveolar mammary gland tumors induced by c-neu, v-Ha-ras, and other oncogenes. As the expression of Cyclin D1 gene is associated with poor prognosis of estrogen receptor (ER) positive patients, which is supported by relapse-free and overall survival, tumor growth in MMTV-Cyclin D1 models is expected to be ER-positive and estrogen-dependent [48,49]. In MMTV-Cyclin D1 mice, mammary adenocarcinoma develops by 22 months of age, which is observed in 40% of the transgenic mice. As Cyclin D1 is a weak oncogene, its expression causes long latency and low incidence of breast cancer in the transgenic mice, and co-expression with potent oncogenes is required for carcinogenesis.

Wnt signaling in human breast cancer has been known to be related to the overexpression of β-catenin. It was also reported that human breast cancers highly express β-catenin which is correlated with poor prognosis of breast cancer patients. In MMTV-Wnt1 transgenic mice, mammary adenocarcinoma develops by 32 weeks of age, which is observed in 60% of the mice, and metastasis to lymph nodes and lungs is observed.

In C3(1)/Tag mice, the SV40 large T-antigen (Tag) is expressed by the regulatory control of the rat prostatic steroid binding protein C3(1) gene, leading to development of prostate tumors in male mice or mammary gland adenocarcinomas in female mice [50]. Characteristics of these models include short latency (~21 weeks) and high penetrance (~90%) (Table 2), which is useful for colony management, as well as nonclinical therapeutic trials. In the transgenic mice, mammary adenocarcinoma develops by 21 weeks of age, which is observed in 90% of the mice. Identification of conserved gene expression features and DNA somatic alterations between the C3(1)/Tag models and human breast tumors suggests that this transgenic model recapitulates human Basal-like cancer (BLBC) [51].

WAP (whey acidic protein) promoter is activated by lactogenic hormones in mammary tumors of mice. Ras oncogene has been known to contribute to human cancer development, and the expression of H-ras oncogene driven by the WAP promoter causes genomic instability, adenocarcinoma, and pulmonary metastasis in mice [52,53]. In the transgenic mice, mammary gland tumors develop at 24 weeks of age (Table 2).

Taken together, GEMMs of breast cancer are essential nonclinical models to understand the expression profile of target genes and to validate novel therapeutic strategies.

**Conclusion**

Breast cancer is the most common type of cancer in females. Despite recent advances in its diagnosis and effective therapeutic strategies, further investigations into tumorigenesis, metastasis, and resistance are urgently required. In this review, we provide an overview of tumor transplantation models and GEMMs in order to understand the molecular mechanisms underlying breast cancer progression and metastasis, and to validate the association of human breast cancer with clinical therapeutic trials. Technological advances in order to develop novel mouse models would give us new insights for developing innovative breast cancer therapeutics.

**Acknowledgments**

This work was supported by the National Cancer Center Grant (NCC-1810042) funded by the Korean government.

**Conflict of interests** The authors declare that there is no financial conflict of interests to publish these results.

**References**

1. Kweon SS. Updates on Cancer Epidemiology in Korea, 2018. Chonnam Med J 2018; 54(2): 90-100.
2. Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-
21. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17(4): 343-359.

22. Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CORT0066101. Mol Cancer Ther 2015; 14(6): 1306-1316.

23. Zhang C, Yan Z, Arango ME, Painter CL, Anderes K. Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 2009; 15(1): 238-246.

24. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52(6): 1399-1405.

25. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro JE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Proctor AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16(1): R7.

26. Ceriani JP, Guillardo T, Giulianelli S, Vaque JP, Guitkun JS, Vanzulli SI, Martins R, Zettlin E, Lamb CA, Lanari C. Interaction between Argonaute2 and the androgen receptor in breast cancer. Breast Cancer Res 2011; 15(10): 3720-3731.

27. Whittle JR, Lewis MT, Lindeman GI, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 2015; 17: 17.

28. Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 2015; 15(8): 451-452.

29. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Melman-GSM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014; 4(9): 998-1013.

30. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Case F, Chatterjee S, Chiang DY, Chuel S, Cogan SM, Collins SD, Dammessa E, Ebel N, Emby M, Green J, Kauffmann A, Koval C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonal F, Merkin J, Meyer R, Nayor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetoto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Better H, Atadja P, Lees E, Hofman F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015; 21(11): 1318-1325.

31. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: an emerging platform for translational cancer research. Cancer Discov 2014; 4(9): 998-1013.
pharmacokinetics of breast cancer therapies. Expert Opin Drug Metab Toxicol 2015; 11(2): 221-230.

36. Singh M, Ramsay I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, Zang X, Aggarwal BB, Gravekamp C. Curcumin improves the therapeutic efficacy of Listeria(αt)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med 2013; 2(4): 571-582.

37. Takahashi K, Nagai N, Ogura K, Tsuneyama K, Saikô I, Irimura T, Hayakawa Y. Mammary tissue microenvironment determines T cell-dependent breast cancer-associated inflammation. Cancer Sci 2015; 106(7): 867-874.

38. Tao K, Fang M, Altrov J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008; 8: 228.

39. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Dufferf J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Hoy E, Barnies M, Long A, Honan C, Qi YW, Shriver Z, Graeme T, Abshire R, Watanabe Y, Oshinowo AM, Hamoto TK. M402, a novel heparan sulfated mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 2011; 6(6): e21106.

40. Hanahan D, Wagner EF, Palmiter RD. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007; 21(18): 2258-2270.

41. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen JC. Identification of conserved gene expression features between the Annapolis meeting. Oncogene 2000; 19(8): 1002-1009.

42. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt RJ. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000; 19(8): 1002-1009.

43. Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Charpin T, Delattre O, Dieras V, Imbert B, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13(13): 3969-3998.

44. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milashi BA, Nelson E, Neumann I, Randall RL, Stijlemans U, Welm BE, Welm AL. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17(11): 1514-1520.

45. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Girls ME. Histopathology of human breast cancer xenografts in stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013; 73(15): 4885-4897.

46. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pineux G, Judde JG, Rebuffi M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13(13): 3969-3998.

47. Hynes NE, MacDonald G. ErbB receptors and signaling pathways. Rev Mol Diagn 2009; 9(5): 423-440.

48. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54(1): 105-115.

49. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pineux G, Judde JG, Rebuffi M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13(13): 3969-3998.

50. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pineux G, Judde JG, Rebuffi M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13(13): 3969-3998.

51. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pineux G, Judde JG, Rebuffi M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13(13): 3969-3998.